5 (241) In stock
Frontiers Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial - ScienceDirect
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study
Joseph P Costantino's research works
PDF) Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D) - ScienceDirect
Frontiers Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial - ScienceDirect
Landmark trials in breast cancer.pptx
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results, BMC Cancer
Final Planned Joint Analysis of Overall Survival from NSABP-B-31 and NCCTG-N9831
